Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800693676> ?p ?o ?g. }
- W2800693676 endingPage "24469" @default.
- W2800693676 startingPage "24457" @default.
- W2800693676 abstract "In this study, we identified microRNAs (miRNAs) involved in cisplatin (CDDP) resistance in bladder cancer (BCa). After establishing CDDP-resistant BCa cell lines (T24RC and EJ138RC), TaqMan arrays revealed that members of the miR-200 family (miR-200b, miR-200a and miR-429) were downregulated in T24RC as compared to parental T24 cells. miR-200b was associated with CDDP sensitivity in BCa cells, and its downregulation was associated with CpG island hypermethylation. Pharmacological demethylation using 5-aza-2'-deoxycytidine restored miR-200b expression, and the combination of 5-aza-2'-deoxycytidine + CDDP strongly inhibited T24RC cell proliferation. Microarray analysis revealed that miR-200b + CDDP induced genes involved in CDDP sensitivity or cytotoxicity, including IGFBP3, ICAM1 and TNFSF10, in the resistant cells. Expression and DNA methylation of miR-200b were inversely associated in primary BCa, and low expression/high methylation was associated with poor overall survival. These results suggest downregulation of miR-200b is associated with CDDP resistance in BCa. Epigenetic silencing of miR-200b may be a marker of CDDP resistance and a useful therapeutic target for overcoming CDDP resistance in BCa." @default.
- W2800693676 created "2018-05-17" @default.
- W2800693676 creator A5003368584 @default.
- W2800693676 creator A5015427845 @default.
- W2800693676 creator A5028583470 @default.
- W2800693676 creator A5039892623 @default.
- W2800693676 creator A5044409221 @default.
- W2800693676 creator A5044510659 @default.
- W2800693676 creator A5064856279 @default.
- W2800693676 creator A5072741648 @default.
- W2800693676 creator A5080167967 @default.
- W2800693676 creator A5083918280 @default.
- W2800693676 date "2018-05-11" @default.
- W2800693676 modified "2023-10-10" @default.
- W2800693676 title "Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer" @default.
- W2800693676 cites W1764242106 @default.
- W2800693676 cites W1923234847 @default.
- W2800693676 cites W1964037817 @default.
- W2800693676 cites W1976324983 @default.
- W2800693676 cites W1988337994 @default.
- W2800693676 cites W1990362215 @default.
- W2800693676 cites W1992814850 @default.
- W2800693676 cites W2002096876 @default.
- W2800693676 cites W2003631713 @default.
- W2800693676 cites W2007283154 @default.
- W2800693676 cites W2008130100 @default.
- W2800693676 cites W2019818362 @default.
- W2800693676 cites W2023260114 @default.
- W2800693676 cites W2025857609 @default.
- W2800693676 cites W2032465254 @default.
- W2800693676 cites W2048547624 @default.
- W2800693676 cites W2048910343 @default.
- W2800693676 cites W2049108030 @default.
- W2800693676 cites W2068523052 @default.
- W2800693676 cites W2073183042 @default.
- W2800693676 cites W2074775091 @default.
- W2800693676 cites W2079909703 @default.
- W2800693676 cites W2089753996 @default.
- W2800693676 cites W2094613637 @default.
- W2800693676 cites W2100531566 @default.
- W2800693676 cites W2101562875 @default.
- W2800693676 cites W2103132731 @default.
- W2800693676 cites W2103257412 @default.
- W2800693676 cites W2105017496 @default.
- W2800693676 cites W2105935489 @default.
- W2800693676 cites W2106958499 @default.
- W2800693676 cites W2121291985 @default.
- W2800693676 cites W2121960517 @default.
- W2800693676 cites W2122562627 @default.
- W2800693676 cites W2125120607 @default.
- W2800693676 cites W2128353922 @default.
- W2800693676 cites W2131090274 @default.
- W2800693676 cites W2136357003 @default.
- W2800693676 cites W2140524200 @default.
- W2800693676 cites W2150322923 @default.
- W2800693676 cites W2154294588 @default.
- W2800693676 cites W2159514748 @default.
- W2800693676 cites W2166453367 @default.
- W2800693676 cites W2171313739 @default.
- W2800693676 cites W2176135723 @default.
- W2800693676 cites W2509204260 @default.
- W2800693676 cites W2588324600 @default.
- W2800693676 cites W2591717879 @default.
- W2800693676 cites W2620431488 @default.
- W2800693676 cites W2620490360 @default.
- W2800693676 cites W2917837889 @default.
- W2800693676 doi "https://doi.org/10.18632/oncotarget.25326" @default.
- W2800693676 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5966259" @default.
- W2800693676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29849953" @default.
- W2800693676 hasPublicationYear "2018" @default.
- W2800693676 type Work @default.
- W2800693676 sameAs 2800693676 @default.
- W2800693676 citedByCount "25" @default.
- W2800693676 countsByYear W28006936762018 @default.
- W2800693676 countsByYear W28006936762019 @default.
- W2800693676 countsByYear W28006936762020 @default.
- W2800693676 countsByYear W28006936762021 @default.
- W2800693676 countsByYear W28006936762022 @default.
- W2800693676 countsByYear W28006936762023 @default.
- W2800693676 crossrefType "journal-article" @default.
- W2800693676 hasAuthorship W2800693676A5003368584 @default.
- W2800693676 hasAuthorship W2800693676A5015427845 @default.
- W2800693676 hasAuthorship W2800693676A5028583470 @default.
- W2800693676 hasAuthorship W2800693676A5039892623 @default.
- W2800693676 hasAuthorship W2800693676A5044409221 @default.
- W2800693676 hasAuthorship W2800693676A5044510659 @default.
- W2800693676 hasAuthorship W2800693676A5064856279 @default.
- W2800693676 hasAuthorship W2800693676A5072741648 @default.
- W2800693676 hasAuthorship W2800693676A5080167967 @default.
- W2800693676 hasAuthorship W2800693676A5083918280 @default.
- W2800693676 hasBestOaLocation W28006936761 @default.
- W2800693676 hasConcept C104317684 @default.
- W2800693676 hasConcept C119056186 @default.
- W2800693676 hasConcept C121608353 @default.
- W2800693676 hasConcept C127561419 @default.
- W2800693676 hasConcept C145059251 @default.
- W2800693676 hasConcept C150194340 @default.
- W2800693676 hasConcept C153911025 @default.